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ABSTRACT	  	  T-­‐0632,	   a	   non-­‐peptidic,	   small	   molecule,	   acts	   as	   an	   inverse	   agonist	   of	   the	   glucagon-­‐like-­‐peptide-­‐1	   (GLP-­‐1)	   receptor.	  	   The	   study	   of	   T-­‐0632	   and	   its	   analogs	   can	   further	   the	  understanding	  of	  the	  structure	  of	  the	  GLP-­‐1	  receptor.	  The	  carboxylic	  acid	  side	  chain	  of	  T-­‐0632	   is	  essential	   to	   the	  biological	   activity,	   as	   shown	  by	   the	   failure	  of	   a	  non-­‐carboxylated	  analog	  to	  inhibit	  binding	  to	  the	  natural	  receptor	  agonist,	  GLP-­‐1.	  The	  work	  presented	  here	  explores	   additional	   modifications	   of	   the	   carboxylic	   side	   chain,	   with	   the	   goal	   of	   further	  refining	  our	  understanding	  of	   the	   role	  of	   this	   functional	   group	   in	   the	   inhibition	  of	  GLP-­‐1	  receptor.	  	  Modifications	  will	   include	  changing	  the	  polarity,	  charge,	  and	  hydrogen	  bonding	  capability	  of	  the	  side	  chain.	  Preparation	  of	  the	  T-­‐0632	  amine	  analog	  is	  described.	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INTRODUCTION	  Diabetes	  Background	  
	   Diabetes	   mellitus	   is	   a	   disease	   that	   affects	   the	   metabolism	   by	   limiting	   the	   body’s	  ability	   to	   process	   blood	   glucose	   levels.	   During	   digestion	   in	   healthy	   humans,	   glucose	   and	  other	  nutrients	  enter	  the	  blood	  stream,	  signaling	  the	  release	  of	  the	  hormone	  insulin	  from	  the	   pancreatic	   β	   cells.	   Insulin	   signals	   cells	   to	   take	   up	   glucose,	   lowering	   the	   amount	   of	  glucose	  in	  the	  blood	  stream.	  Glucose	  is	  a	  necessary	  nutrient,	  the	  primary	  energy	  source	  of	  cells,	  and	  is	  stored	  in	  the	  body	  as	  glycogen.	  Glucagon,	  a	  hormone	  produced	  in	  the	  pancreas,	  is	   responsible	   for	   the	   break	   down	   of	   glycogen	   so	   glucose	   can	   be	   utilized	   for	   energy	  production.	  	  In	   the	   United	   States,	   there	   are	   more	   than	   25	   million	   people	   with	   diabetes.1	   The	  Centers	   for	   Disease	   Control	   and	   Prevention	   (CDC)	   believe	   that	   there	   are	   7	   million	  additional,	   undiagnosed	   cases.1	  A	  quarter	  of	   those	  with	  diabetes	   are	  over	   the	   age	  of	  65.1	  Diabetes	   is	  a	   leading	  cause	  of	  kidney	  failure,	  non-­‐traumatic	   lower-­‐limb	  amputations,	  new	  cases	  of	  blindness,	  heart	  disease,	   stroke,	  and	  death.1	   It	   costs	   the	  United	  States	  over	  $174	  million	   in	   indirect	   and	   direct	   health	   care	   needs.	   Diabetes	   can	   be	   treated	   through	   a	  combination	  of	   therapies	   including	  diet	  management,	  oral	  pills,	   and	  direct,	   subcutaneous	  injection	  of	  insulin,	  other	  hormones,	  and	  their	  analogs.	  	  Diabetes	   is	   characterized	   by	   high	   blood	   glucose	   levels,	   known	   as	   hyperglycemia.	  This	   can	   be	   the	   result	   of	   either	   or	   both	   of	   two	   factors:	   insulin	   resistance	   or	   insulin	  deficiency.	  Type	  I	  diabetes	   is	  an	  autoimmune	  disorder	   in	  which	  the	  pancreatic	  β	  cells	  are	  attacked	   by	   the	   body’s	   immune	   system	   and	   are	   therefore	   rendered	   unable	   to	   produce	  insulin.2	   In	   type	   II	   diabetes,	   also	   known	   as	   non-­‐insulin	   dependent	   diabetes	   mellitus	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(NIDDM)	  and	  adult	  onset	  diabetes,	  the	  pancreatic	  β	  cells	  may	  have	  decreased	  sensitivity	  or	  be	  unresponsive	  to	  glucose	  stimulation	  or	  incretin	  hormones,	  all	  of	  which	  result	  in	  too	  little	  or	  no	  insulin	  production.3	  The	  symptoms	  can	  progress	  to	  the	  deterioration	  of	  the	  β	  cells	  of	  the	  pancreas	  and	  the	  resulting	  loss	  of	  the	  ability	  to	  produce	  insulin,	  similar	  to	  the	  biological	  mechanism	  responsible	  for	  type	  I	  diabetes.	  This	  makes	  blood	  glucose	  homeostasis	  difficult	  to	  maintain	  because	  there	  is	  less	  insulin	  to	  interact	  with	  less	  responsive	  receptors.	  Type	  II	  diabetes	  accounts	  for	  90-­‐95%	  of	  all	  diabetes	  cases.1	  	  One	   treatment	   for	   diabetes	   is	   subcutaneous	   injection	   of	   insulin	   directly	   into	   the	  blood	  stream.	  However,	   insulin	  therapy	  has	  several	  shortcomings,	   including	  the	  necessity	  for	   subcutaneous	   injection,	   a	   short	   half-­‐life	   due	   to	   its	   peptidic	   nature	   and	   requiring	  injections	   more	   than	   once	   per	   day,	   and	   the	   risk	   of	   hypoglycemia.	   Without	   careful	  administration,	  insulin	  can	  cause	  hypoglycemia,	  depleting	  the	  glucose	  sources	  in	  the	  blood	  stream.	   This	   can	   have	   dangerous	   health	   effects.	   The	   brain	   needs	   a	   relatively	   constant	  source	   of	   glucose	   to	   function	   properly	   and	   going	   without	   it	   for	   a	   short	   time	   can	   cause	  serious	  brain	  damage.	  While	  insulin	  injection	  is	  currently	  the	  only	  way	  to	  maintain	  normal	  insulin	  levels	  for	  type	  I	  diabetics,	  there	  are	  other	  options	  for	  those	  with	  type	  II	  diabetes.	  	  	  	  Glucagon-­‐Like-­‐Peptide-­‐1	  and	  Receptor	  Glucagon-­‐like	  peptide-­‐1	  (6/37)-­‐amide	  (GLP-­‐1)	  is	  an	  incretin	  hormone	  produced	  by	  humans	  that	  plays	  an	  essential	  role	  in	  normal	  regulation	  of	  insulin	  and	  glucose	  levels.	  After	  eating	  and	  during	  digestion,	  nutrients	  signal	  the	  release	  of	   incretin	  hormones	  throughout	  the	  intestinal	  tract.	  Endocrine	  cells	  found	  in	  the	  small	  intestine	  (known	  as	  L	  cells)	  produce	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GLP-­‐1	   through	   the	   cleavage	   of	   the	   160-­‐amino	   acid	   protein	   progulcagon,	   initiating	   the	  incretin	  effect.4	  When	  blood	  glucose	  levels	  are	  high,	  GLP-­‐1	  stimulates	  insulin	  release	  from	  the	  pancreatic	  β	  cells.2,	  5	  GLP-­‐1	  inhibits	  glucagon	  release	  and	  improves	  insulin	  sensitivity.5b	  Additionally,	  GLP-­‐1	  encourages	  satiation	  by	  prolonging	  gastric	  emptying5b	  and	  interacting	  with	  neurons	  in	  the	  digestive	  system	  that	  tell	  the	  brain	  it	  is	  satisfied.2	  	  By	  bonding	  with	  the	  GLP-­‐1	  receptor,	  GLP-­‐1	  initiates	  one	  of	  the	  most	  important	  parts	  of	   the	   incretin	   effect:	   starting	   the	   3’-­‐5’	   cyclic	   adenosine	   monophosphate	   (cAMP)	   signal	  cascade	  responsible	  for	  the	  stimulation	  of	  insulin	  release.	  The	  GLP-­‐1	  receptor	  is	  a	  class	  B,	  seven	  transmembrane	  region	  (TM1-­‐TM7)	  G	  protein	  coupled	  receptor	  (GPCR)	  found	  in	  the	  pancreatic	   β	   cells.	   The	   GLP-­‐1	   receptor	   usually	   couples	   with	   Gαs,	   which	   activates	   adenyl	  cyclases,	   increasing	   cellular	   cAMP.6	   A	   distinguishing	   component	   of	   the	   class	   B	   GPCRs,	   in	  comparison	   to	   the	   class	   A	   GPCRs,	   is	   the	   presence	   of	   a	   large	   folded	   globular	   ectodomain	  (ECD)	  at	  the	  N-­‐terminus.7	  Common	  to	  class	  B	  GPCRs	  are	  six	  cysteine	  residues	  located	  in	  the	  ECD.8	   The	   entire	   GLP-­‐1	   receptor	   amino	   acid	   sequence	   has	   been	  mapped	   and	   important	  residues	  are	  well	  known.9	  While	   the	  entire	  amino	  acid	  sequence	  of	   the	  GLP-­‐1	  receptor	   is	  known,	  a	  complete	  high-­‐resolution	  crystal	  structure	  has	  not	  yet	  been	  obtained	  (Figure	  1).7	  As	   a	   structure	   with	   several	   transmembrane	   regions,	   direct	   X-­‐ray	   crystallography	   is	   not	  possible.	  	  Important	  aspects	  of	   the	  receptor	  can	  be	  determined	  through	   interaction	  with	   the	  specific	  ligands.	  The	  GLP-­‐1	  and	  GLP-­‐1	  receptor	  interaction	  is	  generally	  thought	  of	  as	  a	  two-­‐step	  process	  (Figure	  2).	  First	  the	  N-­‐terminal	  of	  the	  receptor	   initiates	  an	  affinity	  trap	  with	  the	  C-­‐terminal	  of	  the	  peptide,	  localizing	  the	  N-­‐terminal	  of	  the	  peptide	  over	  the	  core	  region	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of	  the	  receptor.4	  Consequently,	  the	  C-­‐terminal	  of	  the	  peptide	  binds	  to	  the	  core	  region	  of	  the	  receptor	   causing	   the	   conformational	   change	   in	   the	   receptor	   initiating	   the	   cAMP	   signal	  cascade	  and	  other	  incretin	  effects.8	  It	  has	  been	  shown	  that	  the	  receptor’s	  N-­‐terminal,	  TM1,	  and	  ECL1	  are	  important	  for	  ligand	  binding	  and	  specificity	  (Figure	  1).10	  Specifically,	  residues	  W39,	   K198,	   R190,	   and	   D198	   of	   the	   receptor	   are	   important	   for	   binding.6,	   8,	   10a,	   11	   The	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moieties	   of	   K202	   and	   D215	   are	   believed	   to	   be	   important	   to	   the	   specificity	   of	   the	   GLP-­‐1	  receptor	   for	   GLP-­‐1.10a	   The	   polar	   character	   of	   the	   extracellular	   residue	   K198	   of	   TM2	   is	  especially	   important	   for	   enhancing	   the	   affinity.11,12	   During	   the	   affinity	   trap,	   the	  hydrophobic	  
moieties	   of	   the	   peptide	   are	   responsible	   for	   most	   of	   the	   interactions	   and	   are	   key	  contributors	  to	  ligand-­‐receptor	  affinity.4,	  13	  	  After	  the	  affinity	  trap,	  the	  ligand	  is	  localized	  over	  the	  extracellular	  loops	  (ECL)	  and	  exposed	  residues	  of	  the	  TM	  regions.	  Interactions	  here	  may	  cause	  a	  conformational	  change	  resulting	   in	   the	   transmission	   of	   signal	   from	   the	   receptor	   to	   the	   G	   proteins.4,	   8,	   14	   Studies	  have	  confirmed	  that	  ECL1,	  adjacent	  portions	  of	  the	  TM2,	  and	  TM4	  are	  essential	  for	  GLP-­‐1	  reception.6,	  10a,	  11	  The	  positive	  charges	  from	  residues	  such	  as	  lysine	  and	  arginine	  of	  the	  EC1	  and	   TM3	   are	   critical	   for	   activation	   of	   the	   GLP-­‐1	   receptor.	   Another	   important	   positive	  charge	  of	   the	  receptor	   is	  K288,	  which	  contributes	  to	   its	  affinity	  to	  the	  N-­‐terminal	  of	  GLP-­‐1.11	  The	  moiety	  is	  found	  on	  the	  interior	  face	  of	  TM4,	  which	  allows	  for	  easy	  access	  to	  bond	  with	   other	   nearby	   residues.11	   Because	   K288	   is	   important	   in	   the	   activation	   of	   the	   GLP-­‐1	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receptor,	   it	   could	  be	   an	   important	   residue	   to	   keep	   in	  mind	  when	  developing	   therapeutic	  approaches	  to	  type	  II	  diabetes.11	  Through	  systematic	  analysis	  of	  each	  amino	  acid	  of	  GLP-­‐1,	  Kim	  Adelhorst	  confirmed	  the	  importance	  of	  residues	  H7,	  E9	  G10,	  F10,	  T13,	  and	  D15	  of	  the	  N-­‐terminal	  of	  GLP-­‐1	  for	  binding	  to	  the	  core	  domain	  of	  the	  receptor.13,	  15	  	  Intracellular	  loop	  (IC)	  3	  is	  primarily	  responsible	  for	  transmitting	  the	  signal	  from	  the	  agonist	  to	  the	  G	  proteins.8,	   14	  Particularly	  key	  residues	  are	  K333	  and	  K351.8	  The	  IC3	  does	  not	  act	  exclusively	  as	  it	  is	  believed	  that	  IC1	  and	  IC2	  act	  as	  modulators	  in	  the	  interaction.8	  	  	  GLP-­‐1	  analogs	  and	  GLP-­‐1	  receptor	  agonists	  are	  some	  of	   the	  most	  potent	   therapies	  for	   type	   II	   diabetes	   because	   GLP-­‐1,	   like	   insulin,	   has	   a	   diminished	   presence	   in	   diabetic	  patients	   and	   has	  more	   specific	   effects	   than	   insulin.5a	   Presently,	   it	   is	   unclear	   exactly	   how	  much	  defects	  of	  the	  incretin	  hormones,	  such	  as	  GLP-­‐1,	  play	  a	  role	  in	  diabetes.	  It	  has	  been	  shown	   that	   GLP-­‐1	   in	   type	   II	   diabetics	   is	   less	   abundant	   after	   eating	   than	   in	   healthy	  patients.5aGLP-­‐1	  as	  a	  therapy	  was	  first	  tested	  for	  human	  use	   in	  1987,	  and	  more	  thorough	  analysis	   followed	   in	   1992.5,	   8	   The	   results	   of	   these	   studies	   indicate	   that	   GLP-­‐1	   induces	  insulin	  production	  in	  healthy	  and	  diabetic	  patients.14b	  One	  major	  benefit	  to	  using	  GLP-­‐1	  is	  that	   it	   only	   initiates	   insulin	   production	   and	   release	   when	   blood	   glucose	   levels	   are	   high,	  eliminating	  the	  danger	  of	  hypoglycemia.5a,	  8	  Jens	  Juul	  Holst,	  one	  of	  the	  major	  researchers	  in	  developing	  GLP-­‐1	  therapies	  for	  type	  II	  diabetes,	  found	  that	  GLP-­‐1	  therapy	  can	  fully	  restore	  insulin	   response	   to	   glucose.5a	   In	   addition,	   when	   GLP-­‐1	   is	   used	   as	   a	   therapy,	   it	   can	   have	  trophic	  effects	  on	  pancreatic	  β	  cells	  and	  inhibitory	  effects	  on	  the	  their	  degradation,	  both	  of	  which	  contribute	  to	  the	  recovery	  of	  the	  ability	  to	  produce	  and	  secrete	  insulin	  and	  improved	  production	   and	   reception	   of	   GLP-­‐1.5a,	   16	   Both	   of	   these	   effects	   are	   significant	   for	   patients	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with	   type	   II	   diabetes	   suffering	   from	   an	   insufficient	   number	   of	   β	   cells	   and	   a	   lack	   of	  functioning	  β	  cells.	  These	  trophic	  effects	  have	  been	  clearly	  shown	  in	  animal	  models.16	  	  GLP-­‐1	  was	   the	   first	   non-­‐insulin	   treatment	   option	   and	  was	   the	   starting	  point	   for	   a	  novel	  approach	  to	  diabetes	  treatments.	  A	  potential	  drawback	  to	  this	  therapy	  is	  that	  GLP-­‐1,	  like	   insulin,	   is	   a	   peptide	   with	   a	   short	   half-­‐life	   in	   the	   body	   (less	   than	   two	   minutes).2,	   17	  Additionally,	  less	  than	  one	  third	  of	  natural	  GLP-­‐1	  survives	  the	  departure	  from	  the	  gut	  and	  the	   subsequent	   journey	   to	   the	   pancreatic	   β	   cells.	   When	   GLP-­‐1	   is	   administered	   via	  continuous	   subcutaneous	   infusion,	   only	   10%	   makes	   it	   to	   the	   receptors.5a	   Dipeptidyl	  peptidase	   IV	   (DPP-­‐IV)	   deactivates	   GLP-­‐1	   through	   cleavage	   at	   the	   N-­‐terminal	   at	   H7-­‐A8	  residues	  and	  can	  even	  turn	  it	  into	  an	  antagonist	  of	  the	  GLP-­‐1	  receptor	  (Figures	  3).5a	  
	  Moreover,	  DPP-­‐IV	  is	  the	  sole	  enzyme	  responsible	  for	  the	  degradation	  of	  GLP-­‐1.18	  DPP-­‐IV	  is	  found	  in	  the	  endothelial	  cells	  lining	  blood	  vessels,	  so	  upon	  departure	  from	  the	  gut,	  GLP-­‐1	  is	  immediately	  exposed	  to	  the	  possibility	  of	  cleavage.4	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GLP-­‐1	  Receptor	  Agonists	  and	  DPP-­‐IV	  inhibitor	  Therapies	  Several	  pharmaceutical	  companies	  have	  developed	  analogs	  of	  GLP-­‐1	  with	  the	  goal	  of	  mimicking	  its	  behavior	  while	  extending	  the	  half-­‐life	  by	  establishing	  a	  resistance	  to	  DPP-­‐IV.	  This	  has	  been	  done	  by	  modifying	  the	  important	  residues	  of	  the	  peptide	  required	  for	  DPP-­‐IV	  interaction	   or	   by	   adding	   a	   large	   moiety	   that	   sterically	   hinders	   DPP-­‐IV	   action.	   Through	  modifications	  at	  the	  position	  sensitive	  to	  DPP-­‐IV	  cleavage	  (H7-­‐A8),	  the	  GLP-­‐1	  homology	  is	  maintained	  while	  breakdown	  by	  DPP-­‐IV	  is	  resisted.5a	  In	  addition	  to	  combating	  degradation	  by	   DPP-­‐IV,	   an	   ideal	   peptidal	   therapy	   should	   also	   discourage	   secondary	   degradation	   by	  other	  endopeptidases	  and	  decrease	  the	  facility	  of	  renal	  clearance.4	  	  One	  successful	  GLP-­‐1	  analog	  is	  Exendin-­‐4	  (Figure	  4).	  The	  compound	  was	  originally	  isolated	  from	  a	  peptide	  from	  the	  venom	  of	  a	  lizard	  known	  as	  the	  Gila	  Monster	  (Heloderma	  
Suspectum)	  and	  can	  now	  be	  made	  synthetically.	  With	  a	  glycine	  residue	  in	  the	  penultimate	  position	  of	  the	  N-­‐terminus,	  it	  has	  53%	  homology	  to	  GLP-­‐1,	  behaves	  as	  an	  agonist	  to	  GLP-­‐1,	  and	  is	  resistant	  to	  DPP-­‐IV.4-­‐5	  This	  resistance	  allows	  exendin-­‐4	  to	  have	  a	  half-­‐life	  of	  4	  hours.	  In	  2005,	  exendin-­‐4,	  under	  the	  brand	  name	  Byetta,	  was	  approved	  by	  the	  United	  States	  Food	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and	   Drug	   Administration	   (FDA)	   as	   the	   first	   enteroendrocrine-­‐based-­‐therapy	   for	   type	   II	  diabetes.4	  	  Liraglutide,	  another	  GLP-­‐1	  analog,	  is	  modified	  by	  the	  addition	  of	  an	  acyl	  group	  to	  the	  K26	  position	  of	  GLP-­‐1;	  the	  acyl-­‐group	  is	  then	  palmitoylated	  (Figure	  4).4	  The	  bulky	  fatty	  acid	  moiety	  sterically	  inhibits	  DPP-­‐IV-­‐promoted	  breakdown.	  Liraglutide	  has	  an	  11-­‐15	  hour	  half-­‐life	   due	   to	   its	   insensitivity	   to	   DPP-­‐IV	   and	   an	   innate	   resistance	   to	   renal	   elimination.4-­‐5	  Moreover,	  due	  to	  such	  an	  effective	  resistance	   to	  breakdown,	   it	  can	  be	   taken	  once	  daily,	  a	  definite	   benefit	   to	   liraglutide.19	   Liraglutide	   was	   approved	   by	   the	   FDA	   in	   2010	   for	  therapeutic	  use	  for	  diabetes	  under	  the	  brand	  name	  of	  VictozaI.	  	  Because	   of	   the	   extreme	   and	   exclusive	   degradation	   of	   GLP-­‐1	   by	   DPP-­‐IV,	   some	  pharmaceutical	   companies	   have	   focused	   on	   synthesizing	   drugs	   that	   inhibit	   DPP-­‐IV.	   On	  animal	  subjects	  with	  glucose	   intolerance,	   treatment	  with	  DPP-­‐IV	   inhibitors	  resulted	   in	  an	  improvement	  of	  metabolic	  and	  glucose	  regulation.	  Even	  though	  DPP-­‐IV	  also	  interacts	  with	  other	   substrates,	   its	   extreme	   degradation	   of	   GLP-­‐1	   makes	   it	   the	   ideal	   target.	   There	   is	  evidence	  that	  inhibition	  of	  DPP-­‐IV	  does	  not	  have	  undesired	  side	  effects	  in	  rats.5a	  One	  major	  advantage	  to	  DPP-­‐IV	  inhibitor	  treatment	  is	  that	  the	  drug	  is	  administered	  orally.	  There	  are	  currently	  four	  DPP-­‐IV	  inhibitor-­‐based	  treatment	  options	  available	  in	  the	  United	  States	  and	  the	  European	  Union.	  	  In	   general,	   GLP-­‐1	   receptor	   agonists	   are	   considered	  more	   effective	   due	   to	   the	   fact	  that	   they	   have	   more	   specific	   glycemic	   control.	   Moreover,	   according	   to	   treatment	  satisfaction	  data,	  patients	  are	  more	  satisfied	  with	  GLP-­‐1	  receptor	  agonist	  treatment	  (even	  via	   subcutaneous	   injection)	   than	   the	   DPP-­‐IV	   inhibitors	   due	   to	   the	   superior	   glycemic	  control.19	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Small-­‐Molecules,	   Including	   T-­‐0632	   and	   Analogs,	   as	   GLP-­‐1	   Receptor	   Agonists	   and	  Antagonists	  Another	  option	  for	  the	  treatment	  of	  diabetes	  is	  a	  small-­‐molecule	  agonist	  of	  the	  GLP-­‐1	   receptor.	   Currently	   there	   are	   no	   small	   molecule	   GLP-­‐1	   receptor	   agonist	   therapies	  available	  for	  oral	  administration.7	  An	  ideal	  drug	  therapy	  for	  type	  II	  diabetes	  would	  have	  a	  larger	  half-­‐life	  than	  peptide	  GLP-­‐1	  receptor	  agonists,	  be	  orally	  administered,	  and	  behave	  as	  a	  high-­‐affinity	  GLP-­‐1	  receptor	  agonist.	  There	  are	  currently	  few	  research	  groups	  focusing	  on	  the	  synthesis	  and	  effectiveness	  of	  small	  molecules	  agonists	  of	  GLP-­‐1	  that	  are	  more	  stable	  in	  
vivo	  and	  easily	  administered.6	  Only	  a	  few	  small	  molecules	  are	  known	  to	  interact	  with	  class	  B	  GPCRs,	   let	  alone	  behave	  as	  agonists.6	  It	   is	  difficult	  to	  design	  an	  effective	  small-­‐molecule	  drug	  because	  the	  complete,	  high-­‐resolution	  crystal	  structure	  of	  GLP-­‐1	  receptors	  and	  class	  B	  receptors	   is	   as	   of	   yet	   undeveloped.	   While	   some	   small	   molecules	   have	   expected	  pharmaceutical	  promise,	  others	  have	  been	  useful	  in	  elucidating	  the	  class	  B	  receptor	  crystal	  structure.7	  	  Current	  small-­‐molecule	  agonists	  of	  the	  GLP-­‐1	  receptor,	  including	  some	  quinoxalines,	  thiopenes,	   and	   pyrimidines,	   are	   encouraging,	   but	  most	   have	   several	  metabolic	   liabilities	  and	  more	  biological	   data	  must	  be	   collected	  before	   a	   successful	  molecule	   can	  be	  used	   for	  drug	  treatment.7	  One	  group	  of	  small	  molecule	  agonists,	  azoanthracenes	  (1),	  has	  particular	  potency	  for	  cAMP	  activation	  and	  has	  partial	  agonism	  (Figure	  5).7	  Several	  compounds	  from	  this	   group	   are	   effective	   in	   causing	   insulin	   secretion	   in	   rodents	   with	   type	   II	   diabetes.	   In	  2012,	  the	  leading	  model	  from	  this	  group	  was	  undergoing	  phase	  II	  clinical	  trials.7	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  There	   are	   several	   low	  molecular	  weight	   antagonists,	   about	  which	   little	   is	   known.	  While	   it	  may	   seem	   counterintuitive	   to	   use	   antagonists	   of	   the	   GLP-­‐1	   receptor	   to	   develop	  drugs	  for	  diabetes	  treatment,	  these	  molecules	  could	  be	  useful	  for	  further	  resolution	  of	  the	  crystal	   structure	   of	   the	   GLP-­‐1	   receptor.	   As	   antagonists,	   they	   show	   an	   affinity	   for	   the	  receptor	   and	   may	   elucidate	   critical	   residues	   of	   the	   receptor	   and	   what	   molecular	  requirements	  are	  required	   for	  a	  successful	  drug	   for	   type	   II	  diabetes.	  One	  small	  molecule,	  methyl-­‐3-­‐[1[2(fluorophenyl)-­‐3-­‐(isoquinoline-­‐3-­‐carboxyamido)-­‐6-­‐methoxy-­‐3-­‐yl]propanoate	  (2)	  (referred	  to	  as	  T-­‐0632),	  was	  originally	  studied	  during	  the	  development	  of	   a	   small-­‐molecule	   therapy	   for	  pancreatitis,	  but	   it	  had	  an	  undesired	  side	  effect	  of	  GLP-­‐1	  receptor	  antagonism	  (Figure	  7,	  2).7	  Moreover,	  there	  is	  evidence	  that	  suggests	  that	  T-­‐0632	  reduces	  the	  normal	  activity	  of	   the	  GLP-­‐1	  receptor,	  classifying	   it	  as	  an	   inverse	  agonist.7	  T-­‐0632	  has	  a	  somewhat	  low	  affinity	  for	  the	  GLP-­‐1	  receptor,	  possibly	  making	  it	  ineffective	  for	  furthering	   the	   development	   of	   a	   GLP-­‐1	   receptor	   agonist.7	   However,	   its	   effects	   are	  nonetheless	  potent	  as	  a	  tool	  to	  learn	  about	  the	  receptor.	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  The	  amino	  acid	  residue	  W33,	  part	  of	  the	  folded	  globular	  ECD,	  is	  not	  essential	  for	  normal	  hormonal	  binding,	  but	  it	  plays	  an	  important	  role	  in	  the	  capacity	  of	  T-­‐0632	  to	  interfere	  with	  other	  ligands.6	  This	  important	  residue	  is	  located	  only	  10	  Å	  from	  where	  the	  hydrophobic	  parts	  of	  GLP-­‐1	  usually	  bond.15	  The	  T-­‐0632	  may	  bond	  directly	  at	  W33	  or	  it	  may	  recruit	  other	  receptor	  residues	  to	  create	  a	  ligand-­‐binding	  domain.6	  This	  rearranging	  the	  residues	  of	  the	  receptor	  offers	  a	  possible	  explanation	  for	  the	  molecule’s	  activity	  as	  an	  inverse	  agonist	  interfering	  with	  the	  binding	  site	  conformation	  for	  GLP-­‐1	  binding.	  Either	  way,	  this	  position	  is	  essential	  for	  T-­‐0632	  activity.	  It	  is	  believed	  that	  the	  affinity	  of	  T-­‐0632	  to	  the	  receptor	  is	  due	  to	  stacking	  of	  the	  aromatic	  rings	  of	  T-­‐0632	  and	  W33	  residue	  of	  the	  receptor.6	  	  The	  carboxylic	  acid	  moiety	  of	  T-­‐0632	  is	  hypothesized	  to	  specifically	  bind	  with	  K288,	  of	  TM4,	  and	  several	  histidine	  residues	  found	  in	  ECL1	  and	  the	  exposed	  extracellular	  end	  of	  TM2.11,	  15	  The	  specific	  bonding	  pattern	  of	  T-­‐0632	  with	  the	  ECD	  and	  residues	  of	  the	  TM2,	  ECL1	  and	  TM4	  match	  the	  mechanism	  of	  interaction	  between	  GLP-­‐1	  and	  the	  GLP-­‐1	  receptor.	  These	  major	  bonding	  sites	  make	  up	  the	  known	  interaction	  and	  positioning	  between	  T-­‐0632	  and	  the	  GLP-­‐1	  receptor	  (Figure	  7).	  Through	  further	  study	  of	  T-­‐0632,	  there	  are	  huge	  implications	  for	  an	  improved	  understanding	  class	  B	  GPCR	  interactions	  with	  non-­‐peptide,	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small	  molecules.	  Based	  on	  the	  successes	  of	  class	  A	  GPCR,	  minor	  structural	  modifications	  may	  lead	  to	  active	  agonists,	  even	  when	  the	  original	  analog	  was	  previously	  inactive.6	  	  
	  The	  carboxylic	  acid	  moiety	  of	  T-­‐0632	  is	  thought	  to	  bind	  in	  the	  same	  core	  region	  of	  the	   receptor	   as	   the	  N-­‐terminal	   of	  GLP-­‐1	   is	   known	   to	  bond.	   It	  makes	   sense	   to	  modify	   the	  moiety	  to	  resemble	  this	  region	  of	  the	  peptide	  with	  the	  aims	  of	  imitating	  peptide	  activation	  of	  the	  receptor.	  The	  propyl	  amine	  analog	  of	  T-­‐0632	  (3)	  (known	  as	  T-­‐0632-­‐amine)	  could	  act	  as	  a	  synthetic	  handle	   for	  adding	  amino	  acid	  residues.	  The	  amine	  as	   the	  starting	  point	   for	  the	  addition	  of	   the	  amino	  acids	  allows	  for	  physical	  distance	  between	  the	  main	  body	  of	  T-­‐0632	  and	  the	  binding	  region	  of	  the	  molecule.	  This	  may	  allow	  for	  closer	  GLP-­‐1	  mimicry,	  due	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to	  the	  natural	  separation	  in	  GLP-­‐1	  between	  the	  residues	  necessary	  for	  interaction	  with	  the	  GLP-­‐1	  folded	  globular	  ECD	  and	  the	  residues	  necessary	  for	  bonding	  to	  the	  core	  region	  of	  the	  receptor.	  Analogs	  with	  histidine,	   glycine,	   phenylalanine,	   threonine,	   aspartic	   acid,	   alanine,	  and	  glutamic	  acid	  moieties	  would	  be	  intelligent	  choices	  to	  explore	  because	  these	  are	  known	  to	  be	  essential	  for	  GLP-­‐1–receptor	  affinity	  and	  activation.	  The	  third	  to	  last	  residue,	  glutamic	  acid,	   has	   similar	   properties	   to	   the	   carboxylic	   acid	   moiety	   of	   T-­‐0632.	   Analyzing	   the	  biological	  activity	  of	  an	  analog	  with	  a	  glutamic	  acid	  moiety	  (5)	  can	  help	  clarify	  the	  specific	  role	  of	  the	  polar	  and	  charge	  character	  of	  the	  ligand	  in	  the	  interaction	  with	  the	  receptor.	  An	  analog	  with	  all	  three	  ultimate	  residues	  would	  be	  a	  valuable	  molecule	  to	  explore	  as	  well.	  By	  adopting	  a	  more	  similar	  homology	  to	   the	  peptide,	  amino	  acid	  T-­‐0632-­‐amine	  analogs	  may	  also	  adopt	  similar	  behavior	  and	  act	  as	  agonists	  to	  the	  receptor.	  Another	  option	  is	  exploring	  the	   role	   of	   the	  physical	   distance	  between	   the	  main	  body	  of	   the	  molecule	   and	   the	  moiety	  responsible	   for	   receptor	   agonism.	  This	   could	  be	  done	   through	   the	   synthesis	   of	  4-­‐oxo-­‐(T-­‐0632-­‐amine)-­‐butanoic	  acid	  (6),	  an	  analog	  with	  a	  larger	  alkyl	  chain	  between	  the	  carboxylic	  moiety	  and	  the	  main	  body	  of	  T-­‐0632.	  More	  research	  is	  necessary	  before	  conclusions	  can	  be	  drawn.	  	  As	  mentioned	  above,	  T-­‐0632	  has	  a	  relatively	  low	  affinity	  to	  the	  GLP-­‐1	  receptor.	  Yet,	  it	  still	  has	  benefits	   in	  terms	  of	  furthering	  the	  understanding	  of	  GLP-­‐1	  receptor	  and	  ligand	  interaction	   important	   for	   small-­‐molecule	   agonism.	   An	   important	   tool	   used	   in	   the	  determination	   of	   the	   therapeutic	   potential	   of	   different	   analogs	   of	   T-­‐0632	   is	   the	  cholecystokinin	   (CCK)	   receptor,	   to	  which	   T-­‐0632	   has	   a	   higher	   affinity	   as	   an	   antagonist.7	  The	  CCK	  receptor	  is	  a	  7TM	  GPCR,	  like	  the	  GLP-­‐1	  receptor,	  and	  modulates	  many	  physiologic	  functions,	  such	  as	  the	  secretion	  of	  gastric	  acids	  and	  pain	  perception.	  An	  important	  part	  in	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any	   small-­‐molecule–receptor	   interaction	   is	   the	   affinity	   for	   binding,	   and	   then	   the	   agonist	  mechanism.	  Using	   the	   CCK	   receptor,	   less	   T-­‐0632	  would	   be	   required	   for	   determining	   the	  initial	  affinity	  relationship	  between	  analogs	  and	  the	  GLP-­‐1	  receptor.	  If	  affinity	  is	  achieved,	  the	  T-­‐0632	  analogs	  would	  be	  tested	  for	  GLP-­‐1	  receptor	  activity.	  	  Present	  Research	  The	   research	   presented	   here	   focuses	   on	   synthesizing	   a	   T-­‐0632	   analog	   with	  modifications	   to	   the	   carboxylic	   acid	   moiety.	   Combining	   current	   knowledge	   about	   the	  important	   residues	   involved	   in	   binding	   to	   the	  GLP-­‐1	   receptor,	   the	   known	   and	   suspected	  mechanism	  of	   interaction	   of	   the	   receptor	  with	  T-­‐0632,	   and	   activity	   of	   specific	   analogs,	   a	  more	   sophisticated	   understanding	   the	   GLP-­‐1	   receptor	   and	   a	   more	   efficient	   type	   II	   drug	  therapy	  may	  be	  achieved.	  The	  present	  goal	  is	  the	  synthesis	  of	  T-­‐0632-­‐amine,	  establishing	  a	  molecule	  with	   the	  opposite	   charge	   than	   those	  previously	   studied.	  A	  positive	   charge	  here	  may	   repel	   the	   positive	   residues	   of	   the	   ECLs	   and	   TM4,	   such	   as	   lysine	   and	   histidine.	   The	  possible	  opening	  caused	  by	  this	  repulsion	  may	  lead	  to	  a	  different	  conformational	  structure	  than	   the	  change	  due	   to	   the	  hydrostatic	   repulsion	  of	  T-­‐0632.	  Using	   the	  T-­‐0632	  amine,	  we	  can	   explore	   whether	   electrostatic	   interactions	   play	   a	   significant	   role	   in	   conformational	  changes.	   These	   changes	   may	   result	   in	   changes	   in	   receptor	   activity.	   After	   successful	  synthesis,	   T-­‐0632-­‐amine	   would	   go	   through	   biological	   testing	   to	   determine	   its	   biological	  activity.	   In	  addition	  to	  causing	  possible	  changes	  in	  the	  agonist	  activity,	  T-­‐0632-­‐amine	  is	  a	  good	  starting	  point	  for	  the	  synthesis	  of	  analogs	  with	  amino	  acids.	  Amino	  acids	  can	  be	  easily	  added	  in	  the	  direction	  that	  mimics	  the	  N-­‐terminal	  of	  GLP-­‐1.	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RESULTS	  AND	  DISCUSSION	  The	  synthesis	  of	  T-­‐0632-­‐amine	  (3)	  has	  been	  attempted	  twice.	  The	  entire	  synthesis	  of	  T-­‐0632	  amine	  follows	  the	  same	  procedure	  as	  traditional	  T-­‐0632	  through	  the	  synthesis	  of	  the	  intermediate	  T-­‐07	  (10)	  (Figure	  8).	  From	  T-­‐07,	  T-­‐0632-­‐amine	  is	  synthesized	  via	  Michael	  Addition	  of	  acrylonitrile	  to	  T-­‐07	  followed	  by	  a	  reduction.	  	  
	  Synthesis	  of	  oxime	  Starting	   with	   isatin	   (7)	   previously	   synthesized	   by	   lab	   mates,	   oxime	   (8)	   was	  successfully	  synthesized	  using	  the	  standard	  lab	  technique.	  Via	  a	  condensation	  reaction,	  the	  isatin	  was	  reacted	  with	  hydroxylamine	  hydrochloride	  and	  sodium	  carbonate	  for	  24	  hours	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at	   room	   temperature.	   The	   product	   was	   considered	   pure	   based	   on	   1H-­‐NMR	   analysis.	  Reduction	   to	   the	   amine	  hydrochloride	   (9)	   remained	   elusive	  due	   to	  mechanical	   failure	   of	  the	  catalytic	  hydrogenation	  instrument.	  	  Extra	   stores	   of	   T-­‐07	   were	   available	   in	   lab,	   allowing	   synthesis	   of	   T-­‐0632	   without	  personal	  completion	  of	  the	  beginning	  steps	  of	  the	  total	  synthesis.	  	  	  Michael	  Addition	  to	  form	  T-­‐0632-­‐nitrile	  The	  synthesis	  of	  T-­‐0632-­‐nitrile	  (11)	  was	  accomplished	  through	  a	  Michael	  addition.	  The	   Michael	   addition	   is	   based	   on	   a	   patent	   released	   by	   Yamada	   et	   al,	   in	   1998,	   using	  acrylonitrile	  and	  potassium	  carbonate	  (Figure	  9).20	  Wellesley	  College	  thesis	  students	  Kim	  (’08)	  and	  McLoughlin	  (’14)	  from	  the	  Haines	  Lab	  have	  used	  various	  solvents,	  and,	  through	  trial	  and	  error,	  determined	  that	  reactions	  performed	  in	  either	  dimethyl	  sulfoxide	  (DMSO)	  and	   1,4-­‐
dioxane	   yield	   the	   highest	   amounts	   of	   T-­‐0632	   methyl	   ester	   (71	   and	   90-­‐100%,	  respectively).21	  However,	  with	  other	   acrylates,	   such	   as	   acrylonitrile,	   the	   yield	  was	  not	   as	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high.	  With	  DMSO	  and	  acrylonitrile	  to	  facilitate	  the	  Michael	  addition,	  1H-­‐NMR	  analysis	  of	  the	  crude	  reaction	  mixture	  showed	  almost	  complete	  consumption	  of	  T-­‐07,	  resulting	  in	  a	  yield	  of	  70%	  T-­‐0632-­‐nitrile	  product.	  	  Another	  attempt	  of	  the	  Michael	  addition	  used	  1,4	  dioxane	  as	  the	  solvent.	  The	  major	  product	  of	  this	  attempt	  was	  not	  T-­‐0632	  nitrile,	  but	  possibly	  a	  rearranged	  version	  of	  T-­‐07	  
(12)	   (Figure	   10).	   Chromatography	   was	   attempted	   several	   times	   with	   extended	   periods	  between	   attempts.	   As	   a	   result	   less	   than	   10%	   of	   pure	   T-­‐0632	   nitrile	   was	   isolated.
	  Based	   on	   analysis	   of	   the	   1H-­‐NMR	   and	   13C-­‐NMR	   spectra	   of	   the	   major,	   undesired	  product	   and	   comparison	   with	   1H-­‐NMR	   and	   13C-­‐NMR	   spectra	   of	   T-­‐07	   yielded	   several	  conclusions	   (Appendices	   1-­‐4,	   respectively).	   One	   clear	   conclusion	   is	   that	   the	   acrylonitrile	  never	   bonded,	   evident	   by	   the	   lack	   of	   peaks	   in	   the	   aliphatic	   region	   (δ2.2-­‐2.8	   ppm).	  Additionally,	  the	  secondary	  amide	  α-­‐proton	  is	  no	  longer	  present,	  as	  there	  are	  no	  peaks	  at	  
δ5.9	  ppm	   in	   the	   1H-­‐NMR,	  where	   that	  hydrogen	  would	  be	  expected	   to	  appear.	  The	   lack	  of	  proton	  signal	  could	  be	  the	  result	  of	  an	  elimination	  pathway	  resulting	  in	  a	  double	  bond	  or	  
	  	  
23	  
perhaps	   binding	   between	   the	   nucleophilic	   carbon	   and	   some	   other	   electrophilic	   species.	  However,	   there	   are	   few	   other	   shifts	   in	   the	   NMR	   spectra,	   most	   likely	   eliminating	   the	  possibility	  of	  an	  unexpected	  addition	  or	  polymerization.	  Based	  on	  the	  initial	  1H-­‐NMR	  of	  the	  reaction	  mixture,	  this	  product	  was	  not	  as	  abundant	  because	  the	  proportions	  of	  those	  peaks	  were	   not	   so	   proportionately	   large.	   The	   identity	   of	   this	   product	   is	   most	   likely	   due	   to	   a	  rearrangement	   that	   may	   have	   occurred	   during	   two	   stages	   of	   the	   reaction.	   The	  rearrangement	  could	  have	  resulted	  during	  the	  first	  ten	  minutes	  of	  the	  reaction	  while	  the	  T-­‐07	  was	  under	  basic	  conditions	  and	  before	  the	  acrylonitrile	  was	  added	  (Figure	  10).	  It	  may	  have	  also	  occurred	  during	  period	  of	  time	  the	  crude	  reaction	  mixture	  remained	  on	  the	  silica	  gel	  gravity	  column	  and	  in	  solution.	  Silica	  can	  trap	  molecules	  like	  T-­‐0632	  and	  analogs	  due	  to	  its	   acidic	   nature	   and	   this	   environment	   could	   cause	   the	   rearrangement	   via	   acid	   catalysis,	  which	   has	   a	   very	   similar	   mechanism	   as	   the	   base	   catalysis	   shown	   in	   Figure	   10.	   The	  rearrangement	   allows	   for	   the	   formation	   of	   highly	   energetically	   favorable	   aromatic	   rings.	  While	   we	   have	   a	   predicted	   structure	   for	   the	   possible	   rearrangement,	   none	   of	   the	  predictions	  exactly	  agree	  with	   the	   1H-­‐	  and	   13C-­‐NMR	  spectra	  obtained.	  Based	  on	   the	   large	  amount	   of	   undesired	   product,	   future	   synthetic	   schemes	   should	   eliminate	   the	   first	   time	  period	  of	  basic	  conditions	  without	  the	  acrylonitrile	  and	  the	  products	  should	  be	  processed	  in	  a	  timely	  manner	  and	  kept	  at	  cool	  temperatures	  to	  discourage	  rearrangement.	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Reduction	  of	  T-­‐0632-­‐nitrile	  to	  T-­‐0632-­‐amine	  
Two	   different	   techniques	  were	   used	   for	   the	   reduction	   of	   the	   T-­‐0632-­‐nitrile	   to	   T-­‐0632-­‐amine	   (3)	   (Figure	  11).	   From	   the	  outset,	   it	  was	   anticipated	   that	   the	   chemoselective	  reduction	  would	  be	  difficult	  to	  accomplish	  due	  to	  the	  presence	  of	  several	  other	  unsaturated	  
	  moieties	   within	   the	   molecule.	   Additionally,	   there	   was	   the	   possibility	   of	   rearrangement	  within	  T-­‐0632-­‐amine:	   the	   isoquinoline	   could	   shift	   to	   the	  primary	  amine.	  Many	  published	  techniques	  were	   not	   suitable	   options	   because	   they	   utilized	  materials	   that	   would	   reduce	  carbonyls	  in	  the	  molecule	  or	  result	  in	  secondary	  amines	  and	  dimers	  through	  the	  formation	  of	  aldimines	  (Figure	  12).22	  The	  first	  attempt	  of	  T-­‐0632-­‐amine	  was	  done	  on	  a	  70	  mg	  scale	  and	   utilized	   a	   hydrogenation	   technique	   with	   a	   rhodium	   catalyst.23	   Freifelder	   found	   that	  hydrogenation	   with	   rhodium	   catalysts	   required	   mild	   conditions	   (2-­‐3	   atm)	   compared	   to	  those	  with	  nickel	  (90	  atm).	  Furthermore	  the	  presence	  of	  ammonia	  in	  the	  solvent	  allows	  a	  good	   yield	   of	   primary	   amines,	   discouraging	   the	   formation	   of	   secondary	   amines	   and	  aldimines.	   Due	   to	   scale	   and	   instrument	   restrictions,	   the	   reaction	   was	   performed	   under	  highly	  diluted	  conditions.	  Upon	   1H-­‐NMR	  analysis,	   it	  was	  determined	   that	   there	  may	  have	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been	  minor	  reduced	  products,	  but	  the	  large	  majority	  was	  recovered	  T-­‐0632-­‐nitrile.	  During	   the	   second	   attempt	   of	   the	   reduction,	   a	   technique	   was	   used	   that	   takes	  advantage	   of	   sodium	   borohydride	   and	   cobaltous	   chloride	   (Figure	   11).	   Usually,	   sodium	  borohydride	  is	  inert	  to	  nitriles,	  but	  in	  the	  presence	  of	  transition	  metal	  salts,	  such	  as	  cobalt	  (II)	   chloride,	   reduction	  of	   nitriles	   to	  primary	   amines	   can	  be	   achieved	  with	   good	  yields.24	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The	   complete	   mechanism	   is	   uncertain,	   but	   it	   is	   clearly	   an	   exothermic	   reaction	   and	  hydrogen	   gas	   is	   evolved	   while	   black	   deposits	   of	   cobalt-­‐boride	   (Co2B)	   precipitates24b	  Stephen	   Heinzman	   and	   Bruce	   Ganem	   experimentally	   concluded	   that	   the	   Co2B	   is	  responsible	   for	   coordinating	   the	   functional	   groups	   and	   catalyzing	   the	   heterogeneous	  reduction	   by	   NaBH4.24b	   It	   remains	   unclear	   which	   species	   is	   responsible	   for	   the	   actual	  hydride	   donation.24b	   Purification	   and	   handling	   of	   this	   product	   was	   done	   under	   closely	  controlled	  pH	  and	  primarily	  stored	  in	  cool	  conditions	  to	  prevent	  possible	  rearrangement.	  Analysis	   of	   the	   crude	   product	   via	   1H-­‐NMR	   suggests	   about	   50%	   consumption	   of	   T-­‐0632-­‐nitrile.	  After	  successful	  separation,	  it	  was	  determined	  that	  the	  two	  products	  were	  indeed	  T-­‐0632-­‐amine	   and	   T-­‐0632-­‐nitrile.	  Moreover,	   the	   splitting	   of	   the	   singlet	   that	   represented	   a	  hydrogen	   atom	   of	   the	   N-­‐containing	   aromatic	   ring	   of	   isoquinoline	   of	   T-­‐0632	   nitrile	   (δ8.8	  ppm)	   suggests	   two	   conformations	   in	   which	   the	   primary	   amine	   may	   interact	   with	   this	  hydrogen.	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General	  All	   solvents	   and	   reactants	   were	   purchased	   from	   Sigma-­‐Aldrich	   or	   Alfa-­‐Aesar.	  Catalytic	   hydrogenation	   was	   performed	   using	   a	   Parr	   Instrument	   Company	   Pressure	  Reaction	  Apparatus.	  13C-­‐	  and	  1H-­‐NMR	  spectra	  were	  obtained	  using	  a	  300	  MHz	  Bruker	  WIN-­‐NMR	  Spectrometer	  with	  TMS	  as	   an	   internal	   reference.	  Thin	   layer	   chromatography	   (TLC)	  was	  performed	  on	  Merck	  60-­‐F254	  pre-­‐coated	  silica	  gel	  plates	  and	  analysis	  was	  visualized	  with	   UV	   light	   (254	   nm).	   Flash	   chromatography	   was	   performed	   using	   a	   Biotage	   Flash	  Chromatography	   system	   with	   pre-­‐packed	   Biotage	   Silica	   Cartridges.	   Gravity	   column	  chromatography	   was	   performed	   using	   Sigma-­‐Aldrich	   Silica	   gel	   (0.060-­‐0.2	   mm,	   70-­‐230	  mesh).	  	  	  
Synthesis	   of	   Oxime:	   1-­(2-­fluorophenyl)-­3-­(hydroxyimino)-­6-­methoxyindolin-­2-­one	  
(8)	  The	  oxime	  was	  synthesized	  by	  dissolving	  isatin	  (7)	  (0.400	  g,	  1.476	  mmol),	  hydroxylamine	  hydrochloride	   (0.1088	  g,	   1.476	  mmol),	   and	   sodium	  carbonate	   (0.1716	  g,	   1.476	  mmol)	   in	  5.2	  mL	   of	   ethanol.	   Heat	  was	   used	   to	   improve	   the	   solubility	   of	   the	   isatin	   in	   ethanol.	   The	  reaction	  was	  stirred	  for	  24	  hours	  under	  ambient	  conditions.	  After	  two	  hours	  the	  reaction	  was	  bright	  yellow.	  The	  solution	  was	  quenched	  with	  water	  and	  dried	  via	  vacuum	  filtration.	  The	  identity	  of	  the	  oxime	  (0.300	  g,	  1.095	  mmol,	  74%	  yield)	  was	  confirmed	  via	  1H-­‐NMR.	  1H-­
NMR	  in	  CDCl3	  (Appendix	  5):	  δ3.8	  (s,	  3H,	  -­‐OCH3),	  δ6.2	  (d,	  1H,	  H	  of	  m-­‐anisidine),	  δ6.6	  (d,	  1H,	  H	  of	  m-­‐anisidine),	  δ7.11-­‐7.8	  (m,	  4H,	  H	  of	  fluorobenzene),	  δ8.2	  (d,	  1H,	  H	  of	  m-­‐anisidine).	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Synthesis	   and	   purification	   of	   T-­0632	   nitrile:	   3-­[1-­(2-­fluorophenyl)-­3-­(isoquinoline-­
3-­carboxyamido)-­6-­methoxy-­2-­oxindoline-­3-­yl]propionitrile	  (11)	  in	  DMSO	  The	  T-­‐0632-­‐nitrile	  was	  synthesized	  by	  dissolving	  T-­‐07	  (1)	  (0.100	  g,	  0.234	  mmol)	  in	  1.167	  mL	   of	   acetone.	   DMSO	   (0.038	  mL)	   and	   potassium	   carbonate	   (0.0971	   g,	   3.51	  mmol)	  were	  added	  to	   the	  solution	  and	  stirred	   for	  10	  minutes	  at	  room	  temperature.	  Six	  equivalents	  of	  acrylonitrile	   (0.0924	   mL,	   1.405	   mmol)	   were	   added.	   The	   reaction	   stirred	   for	   24	   hours	  covered	   by	   a	   septum.	  After	   24	   hours,	   the	   crude	   product	  was	  magenta.	   The	   solution	  was	  quenched	  with	  3	  mL	  of	  water,	  neutralized	  to	  a	  pH	  of	  4	  using	  hydrochloric	  acid,	  washed	  with	  dichloromethane,	  dried	  with	  magnesium	  sulfate,	  filtered	  and	  desolvated.	  T-­‐0632-­‐nitrile	  in	  the	  crude	  product	  was	  confirmed	  by	  1H-­‐NMR.	  	  Purification	  of	  T-­‐0632-­‐nitrile	  The	   pure	   T-­‐0632-­‐nitrile	   was	   separated	   from	   the	   crude	   product	   by	   flash	   column	  chromatography.	  The	  crude	  product	  was	  dissolved	   in	  dichloromethane	  and	   loaded	   into	  a	  12+M	  Biotage	  samplet	  holder,	  which	  was	  loaded	  onto	  a	  column	  suspended	  in	  mobile	  phase	  of	   20%	   ethyl	   acetate	   in	   hexanes.	   The	   product	   was	   run	   through	   the	   column	   through	   a	  gradient	   of	   20-­‐60%	  ethyl	   acetate	   over	  456	  mL.	  The	   first	   product	   eluted	   (at	   around	  35%	  ethyl	  acetate)	  was	  the	  desired	  product.	  The	  identity	  of	  T-­‐0632-­‐nitrile	  was	  confirmed	  via	  1H-­‐NMR.	  1H-­NMR	  in	  CDCl3	  (Appendix	  6):	  δ2.3	  (m,	  1H,	  H	  of	  alkyl	  chain),	  δ2.5(t,	  2H,	  H	  of	  alkyl	  chain),	  δ2.7	  (m,	  1H,	  H	  of	  alkyl	  chain),	  δ3.7	  (s,	  3H,	  -­‐OCH3),	  δ6.3	  (s,	  1H,	  H	  of	  m-­‐anisidine),	  δ6.6	  (d,	  1H,	  m-­‐anisidine),	  δ7.3-­‐8.1	  (m,	  1H,	  H	  of	  m-­‐anisidine;	  4H,	  H	  of	  of	  difluorobenzene;	  4H,	  H	  of	  benzene	   of	   isoquinoline),	   δ8.5	   (s,	   1H,	   amine)	   δ8.9	   (s,	   1H,	   H	   of	   N-­‐containing	   ring	   of	  isoquinoline),	  δ9.1	  (s,	  1H,	  H	  of	  N-­‐containing	  ring	  of	  isoquinoline).	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Synthesis	   and	   purification	   of	   T-­0632-­nitrile:	   3-­[1-­(2-­fluorophenyl)-­3-­(isoquinoline-­
3-­carboxyamido)-­6-­methoxy-­2-­oxindoline-­3-­yl]propionitrile	  (11)	  in	  1,4-­dioxane	  The	  T-­‐0632-­‐nitrile	  was	  synthesized	  by	  dissolving	  T-­‐07	  (1)	  (0.500	  g,	  1.170	  mmol)	  in	  10	  mL	  1,4	  dioxane	  with	  potassium	  carbonate	  (0.4859	  g,	  3.51	  mmol).	  After	  stirring	  for	  15	  minutes	  at	  room	  temperature,	  6	  equivalents	  of	  acrylonitrile	  (0.46mL,	  7.02	  mmol)	  were	  added.	  The	  reaction	   stirred	   for	   24	   hours	   covered	   by	   a	   septum.	   The	   crude	   product,	   opaque	  brown/orange	   in	   color,	   was	   quenched	   with	   30mL	   of	   water.	   The	   organic	   product,	   now	  transparent	   and	   yellow,	   was	   washed	   three	   times	   with	   20mL	   of	   dicholoromethane.	   The	  crude	  product	  was	  dried	  using	  magnesium	  sulfate	  and	  filtered	  by	  filter	  paper.	  The	  solvent	  was	  evaporated	   leaving	  an	  orange	   film.	  The	  presence	  of	   the	  desired	  product	   in	   the	  crude	  product	  was	  confirmed	  by	  1H-­‐NMR.	  	  Purification	  of	  T-­‐0632-­‐nitrile	  The	  T-­‐0632-­‐nitrile	  was	  purified	  via	   column	  chromatography.	  A	   flash	   samplet	  was	   loaded	  with	  the	  crude	  T-­‐0632-­‐nitrile	  and	  loaded	  onto	  a	  25	  g	  KP-­‐sil	  –	  SNAP	  cartridge	  suspended	  in	  20%	  ethyl	   acetate	   in	   hexanes.	   The	   column	  was	   run	  with	   a	   concentration	   gradient	   of	   20-­‐40%	  ethyl	  acetate	  in	  hexanes	  over	  135	  mL.	  Then	  90	  more	  mL	  of	  40%	  ethyl	  acetate	  was	  run	  through	   the	   column.	  The	  desired	  product	   eluted	  with	  40%	  ethyl	   acetate	   after	  205	  mL	  of	  eluent.	  Pure	  T-­‐0632-­‐nitrile	  (<10%	  yield)	  was	  confirmed	  via	  1H-­‐NMR.	  	  




Synthesis	  of	  T-­0632-­amine:	  3-­[1-­(2-­fluorophenyl)-­3-­(isoquinoline-­3-­carboxyamido)-­
6-­methoxy-­2-­oxindoline-­3-­yl]propylamine	  (3)	  via	  catalytic	  hydrogenation	  T-­‐06-­‐nitrile	  (0.070	  g,	  0.136	  mmol)	  was	  dissolved	  in	  10	  mL	  of	  ammonia	  (2M	  in	  methanol).	  The	  5%	  rhodium	  on	  alumina	  powder,	   reduced	   (0.0036	  g)	  was	   added	   to	   the	  mixture	   and	  reacted	   under	   2.5	   atm	   for	   two	   hours.	   The	   solution	   was	   filtered	   with	   filter	   paper	   and	  desolvated.	   Upon	   analysis	   via	   1H-­‐NMR,	   there	   was	   almost	   complete	   recovery	   of	   starting	  materials	   with	   trace	   amounts	   of	   T-­‐0632-­‐amine.	   1H-­NMR	   of	   crude	   product	   in	   CDCl3	  (Appendix	  7):	  δ1.8-­‐1.9	  (s,	  2H,	  H	  of	  methyl	  α	  to	  primary	  amine;	  3H,	  H	  of	  primary	  amine	  –	  a	  broad	   peak),	  δ2.3-­‐2.8	   (m,	   4H,	  H	   of	   alkyl	   chain),	  δ3.7	   (s,	   3H,	   -­‐OCH3),	  δ6.3	   (s,	   1H,	  H	   of	  m-­‐anisidine),	   δ6.6	   (d,	   1H,	   m-­‐anisidine),	   δ7.3-­‐8.1	   (m,	   1H,	   H	   of	   m-­‐anisidine;	   4H,	   H	   of	  difluorobenzene;	  4H,	  H	  of	  benzene	  of	  isoquinoline),	  δ8.5	  (s,	  1H,	  H	  of	  secondary	  amine)	  δ8.9	  (s,	   1H,	   H	   of	   N-­‐containing	   ring	   of	   isoquinoline),	   δ9.1	   (s,	   1H,	   H	   of	   N-­‐containing	   ring	   of	  isoquinoline).	  	  
Synthesis	  and	  extraction	  of	  T-­0632-­amine:	  3-­[1-­(2-­fluorophenyl)-­3-­(isoquinoline-­3-­
carboxyamido)-­6-­methoxy-­2-­oxindoline-­3-­yl]propylamine	   (3)	   	   via	   sodium	  
borohydride	  halide	  salt	  T-­‐0632-­‐nitrile	   (0.020	   g,	   0.0391	   mmol)	   and	   cobaltous	   chloride	   hexahydrate	   (0.0186	   g,	  0.0781)	  was	   dissolved	   in	   0.2344	  mL	   of	  methanol.	   To	   aide	   solubility	   of	   T-­‐0632-­‐nitrile	   in	  methanol,	  approximately	  0.5	  mL	  of	  tetrahydrofuran	  was	  added	  and	  the	  reaction	  flask	  was	  heated.	  The	  resulting	  solution	  was	  blue.	  Sodium	  borohydride	  (0.0148	  g,	  0.3906	  mmol)	  was	  slowly	   added	   while	   stirring	   at	   20°C,	   which	   resulted	   in	   a	   black	   solution	   that	   evolved	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hydrogen	  gas	  for	  five	  minutes.	  The	  solution	  was	  stirred	  for	  1	  hour.	  Hydrochloric	  acid	  was	  added	  until	  the	  black	  precipitate	  dissolved,	  resulting	  in	  a	  yellow	  organic	  layer	  and	  a	  rose-­‐colored	  aqueous	  layer.	  Sodium	  hydroxide	  was	  added	  drop	  wise	  in	  order	  to	  create	  a	  solution	  with	   a	   pH	   of	   9.	   The	   organic	   layer	   was	   extracted	   with	   dichloromethane,	   washed	   with	  saturated	  sodium	  chloride	  solution,	  dried	  over	  sodium	  sulfate,	  and	  filtered.	  The	  brown,	  tea-­‐colored	  solution	  was	  desolvated,	  resulting	  in	  a	  brown	  gel.	  The	  product	  was	  dissolved	  in	  20	  mL	  of	  ethanol	  and	  0.5	  mL	  of	  hydrochloric	  acid	  and	  then	  desolvated	  again.	  The	  product,	  a	  brown	  gel,	  was	  dissolved	   in	  5	  mL	  of	  dichloromethane	  and	  1	  mL	  of	  5%	  hydrochloric	  acid.	  The	  aqueous	  portion	  was	  washed	  three	  times	  with	  dichloromethane.	  The	  extracted	  organic	  portion	   was	   dried,	   filtered,	   desolvated,	   and	   determined	   via	   1H-­‐NMR	   to	   be	   recovered	   T-­‐0632-­‐nitrile.	   The	   aqueous	  portion	  was	   then	   treated	  with	   sodium	  hydroxide	   and	  T-­‐0632-­‐amine	   was	   extracted	   with	   dichloromethane,	   dried	   with	   sodium	   sulfate,	   desolvated,	   and	  analyzed	  via	  1H-­‐NMR.	  1H-­NMR	  of	  in	  CDCl3	  (Appendix	  8):	  δ1.3-­‐1.8	  (m,	  3H,	  H	  of	  alkyl	  chain;	  3H,	  H	  of	   primary	   amine	   –	   a	   broad	  peak),	  δ2.2	   (s,	   2H,	  H	  of	   alkyl	   chain),	  δ2.7	   (s,	   1H,	   alkyl	  chain),	  δ3.7	   (s,	   3H,	   -­‐OCH3),	  δ6.2	   (s,	  H	  of	  m-­‐anisidine,	   1H),	  δ6.6	   (d,	   1H,	  H	  of	  m-­‐anisidine),	  
δ7.2-­‐8.0	  (m;	  1H,	  H	  of	  m-­‐anisidine;	  4H,	  H	  of	  fluorobenzene;	  4H,	  H	  of	  benzene	  of	  isoquinoline,	  4H),	  δ8.5	  (d,	  1H,	  amine),	  δ8.9-­‐9.0	  (s,	  1H,	  H	  of	  N-­‐containing	  ring	  of	   isoquinoline:	  2	  singlets	  each	   integrating	   to	  ½,	   due	   to	   two	   conformations),	  δ9.1	   (s,	   1H,	  H	   of	   N-­‐containing	   ring	   of	  isoquinoline).	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